With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The National Institutes of Health is undertaking an extended study of the health effects that East Palestine, Ohio, residents ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

Asian shares were mixed and oil prices advanced Wednesday after the escalation of conflict in the Middle East hit Wall Street ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

President Trump called for Iran’s unconditional surrender and said he wouldn’t target the country’s leader “for now.” Plus: Verve Therapeutics shares soar after Eli Lilly agrees to acquire the ...